CXCL8 and lung carcinoma: Serum CEA and IL-8 showed higher expression in patients with stage III/IV lung cancer (7.07 ng/ml, 45.21 pg/ml) than those in patients with stage I/II lung cancer (2.83 ng/ml, 26.37 pg/ml) (p = 0.000, 0.002), while there were no significant changes in the level of IL-1β or IL-6 between patients with stage I/II (0.54 pg/ml, 4.11 pg/ml) and stage III/IV lung cancer (0.65 pg/ml, 6.21 pg/ml) (p = 0.511, 0.323).